AU2003227521A1 - Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain - Google Patents

Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain

Info

Publication number
AU2003227521A1
AU2003227521A1 AU2003227521A AU2003227521A AU2003227521A1 AU 2003227521 A1 AU2003227521 A1 AU 2003227521A1 AU 2003227521 A AU2003227521 A AU 2003227521A AU 2003227521 A AU2003227521 A AU 2003227521A AU 2003227521 A1 AU2003227521 A1 AU 2003227521A1
Authority
AU
Australia
Prior art keywords
treatment
combination
chronic pain
serotonin reuptake
reuptake inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003227521A
Inventor
Gordon John Blackburn-Munro
Jorgen Scheel-Kruger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU2003227521A1 publication Critical patent/AU2003227521A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003227521A 2002-05-30 2003-05-27 Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain Abandoned AU2003227521A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200833 2002-05-30
DKPA200200833 2002-05-30
PCT/DK2003/000353 WO2003101492A2 (en) 2002-05-30 2003-05-27 Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain

Publications (1)

Publication Number Publication Date
AU2003227521A1 true AU2003227521A1 (en) 2003-12-19

Family

ID=29594979

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003227521A Abandoned AU2003227521A1 (en) 2002-05-30 2003-05-27 Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain

Country Status (2)

Country Link
AU (1) AU2003227521A1 (en)
WO (1) WO2003101492A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
BR0317771A (en) 2002-12-27 2005-11-22 Otsuka Pharma Co Ltd Pharmaceutical composition, use, and method of treating disorders in a patient
AR042806A1 (en) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd COMBINATION OF CARBOSTIRILE DERIVATIVES AND INHIBITORS OF SEROTONINE REABSORTION FOR THE TREATMENT OF ANIMO DISORDERS
AU2005250116B2 (en) * 2004-06-01 2011-01-20 F. Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
WO2019222850A1 (en) * 2018-05-23 2019-11-28 Wex Pharmaceuticals Inc. Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126203A (en) * 1996-03-25 2002-12-01 Lilly Co Eli Pharmaceutical synergistic analgesic compositions comprising olanzapine and another analgesic compound
JP2000507544A (en) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー How to treat pain

Also Published As

Publication number Publication date
WO2003101492A2 (en) 2003-12-11
WO2003101492A3 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
HK1215265A1 (en) Treatment of tnf alpha related disorders tnf
AU2003298043A1 (en) Surface treatment of medical device
PT1485078E (en) Milnacipran for the treatment of irritable bowel syndrome
HK1079426A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
AU2003300791A1 (en) Combination therapy for the treatment of pain
SI1627639T1 (en) Use of COX-2 inhibitors for the treatment of affective disorders
HK1103645A1 (en) New pharmaceutical uses of the lipase inhibitor
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
AUPS082102A0 (en) Therapeutic properties of oils
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
AU2003227521A1 (en) Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
AU2002335027A1 (en) Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors
AU2003266965A1 (en) Use of carboxamides for the treatment of tinnitus
AU2003274359A1 (en) Treatment of fluids
AU2003290363A1 (en) Therapeutic use of selective noradrenaline reuptake inhibitors
AU2003293714A1 (en) Methods for the treatment of chronic pain and compositions therefor
GB0216097D0 (en) Treatment of proliferative disorders
PL372900A1 (en) Treatment of metabolic syndrome
AU2003294697A1 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
GB0210210D0 (en) Treatment of hydrocarbons
AU2003224052A1 (en) Compositions comprising mmp7 modulators for the treatment of chronic pain
AU2002320295A1 (en) Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
AU2002318205A1 (en) Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines
EG23218A (en) Dento-oral gel of meloxicam for treatment of oral inflammation.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase